---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-048141"
form_type: "8-K"
ticker: "EMMA"
cik: "0000822370"
company_name: "Emmaus Life Sciences, Inc."
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-24T00:10:12.628661+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Emmaus Life Sciences reports Q2 2022 net loss of $8.9M; warns of insufficient working capital for 12 months

## Summary
- Net revenues Q2 2022 $4.3M, down 34% YoY from $6.5M; sequentially up 33% from Q1 2022 $3.2M.
- Net loss Q2 2022 $8.9M ($0.18/sh) vs net income $2.5M ($0.05/sh) in Q2 2021.
- Cash and equivalents $1.0M at June 30, 2022, down from $2.3M at Dec 31, 2021.
- Management says working capital insufficient for next 12 months without restructuring or new financing.
- In discussions to restructure indebtedness; awaiting Saudi marketing approval decision.

## SEC filing metadata
- accession: 0001213900-22-048141
- form_type: 8-K
- ticker: EMMA
- cik: 0000822370
- company_name: Emmaus Life Sciences, Inc.
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/822370/000121390022048141/0001213900-22-048141-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/822370/000121390022048141/ea164264-8k_emmauslife.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-048141
- JSON: https://secwatch.observer/filing/0001213900-22-048141.json
- Plain text: https://secwatch.observer/filing/0001213900-22-048141.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.